CureVac Shareholders Face Pivotal Decision on BioNTech Takeover Bid
Published on 11/13/2025 at 20:08 | Redaktion boerse-global.de
The acquisition drama surrounding German biopharmaceutical firm CureVac approaches its climax as investors prepare for a landmark shareholder vote. With regulatory hurdles cleared and critical deadlines looming, stakeholders must determine whether to accept BioNTech’s substantial share-exchange proposal.
German financial authorities have removed the final obstacle to the takeover process. The Federal Financial Supervisory Authority (BaFin) approved a crucial amendment to the exchange offer on November 11, paving the way for CureVac’s extraordinary general meeting scheduled for November 25. This gathering will represent a defining moment for the company’s investors.
Shareholders who previously committed to the arrangement maintain withdrawal rights until November 14, introducing a final opportunity for Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
